Dr. Reagan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
593 Eddy St
George Bldg 3RD FL 302
Providence, RI 02903Phone+1 401-444-5435Fax+1 401-444-5392
Summary
- I work primarily with benign and malignant hematological disorders. I am also involved in research in which we give patients with resistant leukemia or lymphoma half matched donor cell infusions. The patients reject the donor cells and in the process retrain their own immune system cells to recognize the tumor.
Education & Training
- Brown UniversityFellowship, Hematology and Medical Oncology, 2010 - 2013
- Brown UniversityChief Residency, Internal Medicine, 2009 - 2010
- Brown UniversityResidency, Internal Medicine, 2007 - 2009
- Brown UniversityInternship, Internal Medicine, 2006 - 2007
- SUNY Upstate Medical UniversityClass of 2006
Certifications & Licensure
- RI State Medical License 2006 - 2026
- MA State Medical License 2011 - 2011
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Special Fellow in Clinical Research The Leukemia and Lymphoma Society, 2013
- Arnold P. Gold Humanism Society 2005
Clinical Trials
- Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma Start of enrollment: 2013 Mar 01
- Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis Start of enrollment: 2013 May 01
- Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias Start of enrollment: 2018 Oct 29
- Join now to see all
Publications & Presentations
PubMed
- 51 citationsBortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.Jorge J. Castillo, Thomas Guerrero-Garcia, Francesco Baldini, Emmanuelle Tchernonog, Guillaume Cartron
British Journal of Haematology. 2019-02-01 - 98 citationsPlasmablastic Lymphoma: A Systematic ReviewJorge J. Castillo, John L. Reagan
Thescientificworldjournal. 2011-03-22 - 32 citationsOverexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemia.Anna Chorzalska, Nagib Ahsan, R. Shyama Prasad Rao, Karim Roder, Xiaoqing Yu
Molecular Oncology. 2018-05-01
Abstracts/Posters
- Bendamustine-Rituximab Does Not Improve Survival over Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone LymphomaJohn L. Reagan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Tumor-Specific Cell-Free DNA (cfDNA) in the Cerebrospinal Fluid (CSF) Detects Cytologically Occult Central Nervous System (CNS) Involvement in Aggressive LymphomasJohn L Reagan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Comparative Effectiveness of Lenalidomide, Bortezomib, and Their Combinations As First-Line Treatment of Older Patients with MyelomaJohn L. Reagan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Loss of Abelson Interactor-1 Is Linked to Inflammatory Hematopoiesis and Accelerated Aging of Hematopoietic System2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Outcomes Associated with Antimicrobial Use during High Dose Cytarabine Consolidation in Acute Myeloid Leukemia2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
- Lifespan Cancer Institute Secures Key Approval for Stem-Cell Therapy for Cancer PatientsJune 21st, 2022
- Lifespan’s Sickle Cell Clinic Considered a One-Stop Shop for PatientsSeptember 23rd, 2021
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: